Co-Diagnostics, Inc. (LON:0A50)

Market Cap	17.81M
Revenue (ttm)	5.46M
Net Income (ttm)	-30.80M
Shares Out	n/a
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183
Average Volume	2,301
Open	0.687
Previous Close	0.670
Day's Range	0.687 - 0.707
52-Week Range	0.560 - 1.765
Beta	n/a
RSI	44.60
Earnings Date	Mar 14, 2025

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 155
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A50

Financial Performance

In 2023, Co-Diagnostics's revenue was $6.81 million, a decrease of -80.09% compared to the previous year's $34.22 million. Losses were -$35.33 million, 148.2% more than in 2022.

Financial numbers in USD